Please Wait
Applying Filters...
menu
    • menu
    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Nerandomilast

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FDA Approves JASCAYD Tablets For Progressive Pulmonary Fibrosis
    FDA Approves JASCAYD Tablets For Progressive Pulmonary Fibrosis

    22 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/us-fda-approves-jascayd-nerandomilast-tablets-for-the-treatment-of-progressive-pulmonary-fibrosis-in-adults-302647964.html

    PR NEWSWIRE
    22 Dec 2025
    Share Share
    Boehringer Ingelheim Pharma’s Jascayd Receives Approval in US
    Boehringer Ingelheim Pharma’s Jascayd Receives Approval in US

    19 Dec 2025

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220449

    FDA
    19 Dec 2025
    Share Share
    FDA Approves JASCAYD Tablets For Progressive Pulmonary Fibrosis
    FDA Approves JASCAYD Tablets For Progressive Pulmonary Fibrosis

    19 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/19/3208710/0/en/U-S-FDA-approves-JASCAYD-nerandomilast-tablets-for-the-treatment-of-progressive-pulmonary-fibrosis-in-adults.html

    GLOBENEWSWIRE
    19 Dec 2025
    Share Share
    JASCAYD Gains First Approval for Pulmonary Fibrosis in China
    JASCAYD Gains First Approval for Pulmonary Fibrosis in China

    10 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/10/3202994/0/en/JASCAYD-nerandomilast-receives-first-regulatory-approval-for-progressive-pulmonary-fibrosis-in-China.html

    GLOBENEWSWIRE
    10 Dec 2025
    Share Share
    Jascayd Approved in China for The Treatment of IPF
    Jascayd Approved in China for The Treatment of IPF

    22 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/22/3170892/0/en/JASCAYD-nerandomilast-approved-in-China-for-the-treatment-of-idiopathic-pulmonary-fibrosis-IPF.html

    GLOBENEWSWIRE
    22 Oct 2025
    Share Share
    Boehringer Ingelheim Picks Orsini as Jascayd Specialty Pharmacy
    Boehringer Ingelheim Picks Orsini as Jascayd Specialty Pharmacy

    14 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/orsini-selected-as-specialty-pharmacy-partner-for-boehringer-ingelheims-jascayd-nerandomilast-302582054.html

    PR NEWSWIRE
    14 Oct 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.